ArticleAmerican journal of medicine open2026
Inpatient NSAID Exposure and Development of Acute Kidney Injury in Medical Inpatients: A Retrospective Cohort Study.
Article in American journal of medicine open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the risk of hospital-acquired acute kidney injury after nonsteroidal anti-inflammatory drug (NSAID) administration in the general medical population. Methods: This was a retrospective cohort study conducted at an academic medical center (Mayo Clinic, Rochester, MN) that included all general care medical patients for 2 years. Patients were analyzed in a propensity-adjusted approach using inverse probability of treatment weighting (IPTW) according to NSAID exposure on hospital day 0 or 1 categorized as follows: (1) no NSAID exposure; (2) only low-dose aspirin; (3) topical exposures, or (4) systemic NSAIDs. Results: A total of 17,885 patients met the initial inclusion criteria, and 11,840 were included in the study. The systemic NSAID cohort were the healthiest and youngest patients at baseline with fewer comorbidities. After adjustment, there was no significant difference seen in the rate of AKI (using the inverse probability of treatment weighting) between cohorts. The odds ratio of hospital-acquired AKI was 1.16 (0.80-1.70) in the Low-dose Aspirin group, 0.65 (0.21-2.03) in the Topical group, and 0.82 (0.27-1.85) in the Systemic NSAID group, with the No NSAID serving as the reference. Adjusted AKI incidence was 3.4% with No NSAIDs, 3.9% with Low-dose Aspirin, 2.2% with Topicals, and 2.8% with Systemic NSAIDs. These differences were not statistically significant. Conclusion: This study provides evidence that carefully selected hospitalized patients may be able to receive NSAIDs without increasing their AKI risk. This increases options for the treatment of pain, which may improve patient satisfaction and decrease opioid-related complications. Further prospective research is required to verify the findings of our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.